• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Fast-acting TB drug cocktail shows great promise

Fast-acting TB drug cocktail shows great promise

July 27, 2012
CenterWatch Staff

Phase II results from a novel anti-tuberculosis drug cocktail—PA-824, moxifloxacin and pyrazinamide—show the elimination of 99% of the Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), found in patients’ saliva following just two weeks of treatment.

The study, funded by the non-profit TB Alliance, provides a stark contrast to the six-month treatment regimen of TB therapies currently on the market. Compliance problems with patients prescribed current TB-related therapy have resulted in the emergence of drug-resistant TB strains, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). A shorter course of therapy is likely to decrease treatment costs while increasing patient compliance.

TB strains resistant to rifampicin and isoniazid are a growing concern, but the new cocktail consists of drugs with different mechanisms of action from both rifampicin and isoniazid, giving it therapeutic leverage against MDR-TB and XDR-TB. The cocktail was effective against both treatment-sensitive and drug-resistant TB in the phase II trial, but more detailed studies in larger patient populations are required to assess its safety and toxicity profile and efficacy against drug-resistant TB.

An ongoing phase IIb trial to study the drug cocktail in a larger population over a two-month treatment regimen is being conducted in South Africa, Brazil and Tanzania. If the trial produces similar results to the phase II trial, developers will likely attempt to fast-track FDA approval via the GAIN Act, which prioritizes antimicrobial therapies for indications with pressing medical need.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing